Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"A reformaltion into a gel or foam enema will be quicker and the trial should be faster."

"Brilacidin is being developed as a novel, non-corticosteroid, non-biologic treatment, with formulation plans including oral tablets for Ulcerative Colitis and Crohn’s Disease, and foam and/or gel for mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD."

Why would a reformulation be necessary when "a majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS"?

If quicker is what you're looking for why not run the trial with the existing product?
I'm pretty sure you would ask that question if you were still doing management interviews.



"In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug’s efficacy. In late 2018, the Company presented a scientific poster—Brilacidin for Inflammatory Bowel Disease (available for download here, pdf)—at the inaugural “IBD Innovate 2018” conference, hosted by the Crohn’s & Colitis Foundation. Brilacidin may be particularly beneficial in treating IBD due to: its ability to inhibit Phosphodiesterase 4 (PDE4), which is being pursued as a novel therapeutic avenue in IBD; and its potential to compensate for defensin deficiencies that are implicated in the pathogenesis of IBD."
http://www.ipharminc.com/press-release/2019/6/6/innovation-pharmaceuticals-signs-agreement-for-advanced-oral-tablet-technology-in-treating-inflammatory-bowel-disease